NR4A3 and acute myeloid leukemia: Dihydroergotamine, an ergot alkaloid used in the clinic to treat migraine, and alprostadil (ALP), also called prostaglandin E1 (PGE1), have been shown to induce NOR1 expression in AML cells by recruiting the superelongation complex to allow elongation of the NOR1 promoter, which pauses (Table 1) (Boudreaux et al., 2019).